Abstract:Abstract Background The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease. Miri demonstrated statistically significant improvements in co-primary and all key secondary endpoints versus (vs) PBO1. Here we present the results of secondary endpoints on the comparisons of miri to ustekinumab (uste), a p40 directed anti-IL-12/IL-23 inhibitor from the Phase 3, randomised, double-blind, double-dummy, active- and PBO-controlled, treat-through (TT) study, VIVID-1 (NCT03926130). Methods Adult pts (N=1065) were randomised 6:3:2 to miri (N=579) 900mg intravenously (IV) every 4 weeks (Q4W) to W12, then 300mg subcutaneously (SC) Q4W to W52, uste (N=287) one ~6 mg/kg IV dose, then 90mg SC Q8W to W52 or PBO (N=199). At W12 PBO responders continued PBO to W52; PBO non-responders received the same blinded miri regimen as described above (IV then SC). Efficacy of miri vs uste was assessed by the proportion of pts achieving endoscopic response and by the proportion of pts achieving clinical remission by Crohn’s Disease Activity Index (CDAI) at W52 (both gated). Additional non-multiplicity-adjusted endpoints included endoscopic remission, corticosteroid-free clinical remission by CDAI, and the composite of CDAI clinical remission and endoscopic response at W52. (Figure 1 for definitions). Results Baseline characteristics were overall balanced across the three treatment groups (table 1). Pts treated with miri achieved all key major secondary endpoints (p<.000001) compared to PBO (Figure 1). Miri achieved non-inferiority to uste for clinical remission by CDAI (p=0.113117) (Figure 1C). Although superiority to uste in endoscopic response was not achieved (p=0.51) (Figure 1A), in biologic failed pts miri demonstrated a numerical trend towards greater response rates compared to uste for endoscopic response and clinical remission by CDAI (Figure 1 B & D). The overall safety profile was consistent with the known safety profile of miri. The proportion of treatment emergent adverse events (TEAE) were similar for miri (78.6%) and uste (77.3%); most common TEAEs were COVID-19, anaemia, arthralgia, headache, upper respiratory tract infection, nasopharyngitis and injection site reaction. Instances of serious adverse events were comparable for miri (10.3%) and uste (10.7%). Conclusion In this phase 3 TT design study, miri achieved non-inferiority to uste for clinical remission by CDAI. In biologic failed pts miri had a numerical trend towards greater response compared to uste in clinical and endoscopic endpoints, with an acceptable safety profile. 1Ferrante et al., submitted to ECCO 2024

What problem does this paper attempt to address?

The main purpose of this paper is to evaluate the efficacy and safety of mirikizumab (an antibody against the IL - 23 p19 subunit) and ustekinumab (an inhibitor against the IL - 12/IL - 23 p40 subunit) in patients with moderate - to - severe Crohn's disease. Specifically, the study aims to determine whether mirikizumab is non - inferior or superior to ustekinumab by comparing the effects of the two drugs in inducing clinical remission and endoscopic response. ### Research Background The primary objective of the VIVID - 1 trial (NCT03926130) was to compare the effectiveness and safety of mirikizumab and placebo in patients with moderate - to - severe Crohn's disease. Previous studies have shown that mirikizumab was significantly superior to placebo in both the primary endpoint and all key secondary endpoints. This paper further reports the results of the secondary endpoint comparison between mirikizumab and ustekinumab. ### Research Methods - **Research Design**: This was a phase III, randomized, double - blind, double - dummy, active - controlled and placebo - controlled treat - through (TT) study. - **Subjects**: A total of 1,065 adult patients with moderate - to - severe Crohn's disease were enrolled. - **Grouping**: - **Mirikizumab group** (N = 579): Intravenous injection of 900 mg every 4 weeks until week 12, followed by subcutaneous injection of 300 mg every 4 weeks until week 52. - **Ustekinumab group** (N = 287): Initial intravenous injection of approximately 6 mg/kg, followed by subcutaneous injection of 90 mg every 8 weeks until week 52. - **Placebo group** (N = 199): Received placebo until week 12, and non - responders to placebo at week 12 were switched to receive mirikizumab treatment (intravenous injection first, followed by subcutaneous injection). - **Assessment Indicators**: - Primary assessment indicator: Proportion of patients achieving endoscopic response and clinical remission (according to the Crohn's Disease Activity Index, CDAI) at week 52. - Other assessment indicators: Endoscopic remission, steroid - free clinical remission, composite endpoints of CDAI clinical remission and endoscopic response. ### Research Results - **Baseline Characteristics**: The baseline characteristics of the three groups of patients were generally balanced. - **Main Findings**: - **Mirikizumab vs Placebo**: Mirikizumab was significantly superior to placebo in all key secondary endpoints (p < 0.000001). - **Mirikizumab vs Ustek**: - Clinical remission (CDAI): Mirikizumab was non - inferior to ustekinumab (p = 0.113117). - Endoscopic response: Mirikizumab did not show superiority over ustekinumab (p = 0.51), but in patients with biologic failure, mirikizumab showed a trend of higher response rate. - **Safety**: The safety of mirikizumab was consistent with the known safety. The incidence of treatment - emergent adverse events (TEAE) was similar in the mirikizumab group (78.6%) and the ustekinumab group (77.3%). The most common TEAE included COVID - 19, anemia, arthralgia, headache, upper respiratory tract infection, nasopharyngitis and injection - site reactions. The incidence of serious adverse events was also similar between the two groups (10.3% in the mirikizumab group and 10.7% in the ustekinumab group). ### Conclusion In this phase III treat - through design study, mirikizumab was non - inferior to ustekinumab in CDAI clinical remission. For patients with biologic failure, mirikizumab showed a trend of higher response rate in clinical and endoscopic endpoints and had an acceptable safety profile.

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

S1051 Efficacy of Mirikizumab by Baseline Disease Location in Moderately to Severely Active Crohn's Disease: Results of the Phase 3 VIVID-1 Study

OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

S1452 Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 VIVID-1 Study

DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

P1044 Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn’s Disease

DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity

S1466 Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn's Disease in Phase 2 and 3 Studies

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme

Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis

Mirikizumab: A promising breakthrough in Crohn's disease treatment

P932 Corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active Ulcerative Colitis: Extended induction subgroup analysis from Phase 3 trial

S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn's Disease

P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials

P568 Clinical relevance of baseline and change in Urgency Numeric Rating Scale score for mirikizumab treatment for Ulcerative Colitis

P046 Real-world data on the treatment with Mirikizumab in a mostly biological-experienced Ulcerative colitis cohort

Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis

S1351 Improvement in Fatigue With Mirikizumab Therapy and Associations With Clinical Outcomes in Patients With Moderately to Severely Active Crohn's Disease: Results From the PHASE 3 VIVID-1 Study

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease